Synlogic Inc (NAS:SYBX)
$ 1.72 -0.03 (-1.71%) Market Cap: 20.00 Mil Enterprise Value: -10.12 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 45/100

Synlogic Inc To Announces Proof of Concept for SYNB8802 in Enteric Hyperoxaluria call Transcript

Dec 15, 2022 / 01:30PM GMT
Release Date Price: $11.04 (+8.28%)
Operator

Welcome to the Conference Call for Synlogic's Proof of Concept Data for SYNB8802 for Enteric Hyperoxaluria. (Operator Instructions)

I would now like to turn the call over to Andrew Funderburk of Kendall Investor Relations.

Andrew Funderburk

Thank you, operator. Good morning, and thank you for joining us on today's conference call. This morning, we issued a press release, which announced our proof of concept data for SYNB8802 in enteric hyperoxaluria. The release is available on the Investors section of our website at www.synlogictx.com.

As we begin, I'd like to remind everyone that comments today may include forward-looking statements made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date hereof and are subject to numerous factors, assumptions, risks and uncertainties, which change over time. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot